Unicycive Therapeutics, Inc. UNCY

4.70 (0.11) (2.29%) as of 25 Sep
Market cap
$134.0M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
P/E ratio
— — 0.00 0.00 — — — — —
P/S ratio
— — 0.00 0.00 — — — — —
P/FCF ratio
— — 0.00 0.00 — — — — —
P/Operating CF
— — (4.90) (1.24) — — — — —
P/B ratio
— — 0.00 0.00 — — — — —
Price to Tangible BV
— — 0.00 0.00 — — — — —
EV/Sales
— — 0.00 0.00 — — — — —
EV/EBITDA
— — 0.00 0.00 — — — — —
EV/Operating CF
— — (0.68) (0.46) — — — — —
EV/FCF
— — (0.68) (0.46) — — — — —
Quick Ratio
2.18 1.08 0.55 0.14 7.88 0.00 0.02 0.02 —
Current Ratio
2.59 1.28 0.76 0.81 8.75 0.07 0.02 0.02 —
Net Debt/EBITDA
1.43 0.83 0.47 0.02 1.94 (0.54) (0.24) (1.07) —
Debt/Assets
0.00% 0.00% 0.00% 5.50% 0.81% 483.33% 2,421.05% 3,610.34% 0.00%
Debt/Equity
0.00 0.00 0.00 (0.33) 0.01 (0.37) (0.52) (0.87) —
Asset Turnover
0.00 0.00 0.08 0.09 0.00 0.00 0.00 0.00 —
Operating CF/Net income
1.18 0.76 0.58 0.87 0.58 0.64 0.54 0.69 —
Capex/Depreciation
(0.04) (0.17) (0.04) (0.01) (0.06) 0.00 0.00 — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(141.14%) (2,088.57%) 1,469.52% (225.47%) (145.04%) 127.37% 207.18% 0.00% —
ROA
(65.73%) (164.96%) (369.35%) (167.50%) (105.73%) (2,030.49%) (9,020.83%) (7,724.14%) —
ROIC
0.00% 0.00% 0.00% 0.00% (10,018.97%) 0.00% 0.00% 0.00% —
Return on Tangible Assets
(88.25%) (547.94%) 764.44% 2,922.01% (61.33%) 84.76% 244.91% 92.87% —
Average Days of Receivables
— — 0.00 0.00 — — — — —
Research and Development Expense of Revenue
0.00% 0.00% 1,911.41% 1,307.68% 0.00% 0.00% 0.00% 0.00% —
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 1,266.22% 690.54% 0.00% 0.00% 0.00% 0.00% —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 261.78% 110.09% 0.00% 0.00% 0.00% — —
Graham Net Nets
— — (0.21) (0.08) — — — — —
Graham Number
— — 23.27 9.14 — — — — —
Earnings Yield
— — (174.94%) (240.00%) — — — — —
Free Cash Flow Yield
— — (84.15%) (207.92%) — — — — —
Revenue per Share
0.00 0.00 0.28 0.63 0.00 0.00 0.00 0.00 —
Operating CF per Share
(1.97) (4.27) (7.45) (10.39) (4.94) (1.72) (1.45) (0.05) —
Capex per Share
0.00 (0.01) 0.00 0.00 (0.02) 0.00 0.00 0.00 —
Free Cash Flow per Share
(1.97) (4.28) (7.46) (10.40) (4.96) (1.72) (1.45) (0.05) —
Cash per Share
2.60 3.90 3.95 0.30 14.20 0.00 0.02 0.00 —
Shareholders Equity per Share
1.90 1.11 (1.55) (0.31) 14.12 (3.14) (1.09) (0.08) —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
1.90 1.11 (1.55) (0.31) 14.12 (3.14) (1.09) (0.08) —
Free Cash Flow
(31.34) (28.65) (18.29) (15.65) (5.80) (1.46) (1.18) (0.77) —
Working Capital
30.02 6.83 (4.13) (0.64) 16.31 (2.67) (0.88) (1.21) —
Capital Expenditures
(0.02) (0.07) (0.01) 0.00 (0.03) — — — —
Net Current Asset Value
30.02 6.71 (4.60) (0.64) 16.15 (2.67) (0.88) (1.21) —
EV/EBIT
— — 0.00 0.00 — — — — —
Capex to Sales
0.00 0.00 0.02 0.00 0.00 — — — —
Net Profit Margin
0.00% 0.00% (4,653.48%) (1,898.84%) 0.00% 0.00% 0.00% 0.00% —
Price to Operating Income
— — 0.00 0.00 — — — — —
Other line items
Depreciation/Fixed assets
8.67 5.71 10.92 7.32 17.89 0.00 0.00 — —
Cash ROIC
(43.91%) (85.34%) (310.74%) (10,884.03%) (17.45%) 86.59% 287.53% 578.36% —
Accounts Receivable Turnover
— — 0.00 0.00 — — — — —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — —
Inventory Turnover
— — — 0.00 0.00 — — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Days of Inventory on Hand
— — — 0.00 0.00 — — — —
Average Payables
0.72 0.95 0.87 0.82 0.46 0.25 0.19 — —
Average Assets
40.40 22.93 8.50 10.78 9.47 0.11 0.02 0.01 —
Average Common Equity
18.81 1.81 (2.14) 8.01 6.91 (1.78) (1.04) — —

Fold the line items

Columns are period end dates